Clinical Trial Update: CD19-redirected Autologous Cells (CAR-CD19 T Cells) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on autologous CAR-CD19 T cells targeting CD19-positive malignant B-cell leukemia and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CAR-CD19 T cells (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: RenJi Hospital | Conditions: CD19 Positive Malignant B-cell Leukemia and Lymphoma | Phase 1 | Status: UNKNOWN